Financial Review: Elicio Therapeutics (ELTX) and The Competition

Elicio Therapeutics (NASDAQ:ELTX) is one of 607 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its competitors? We will compare Elicio Therapeutics to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk.

Volatility & Risk

Elicio Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Elicio Therapeutics’ competitors have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.

Insider and Institutional Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 12.1% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Elicio Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Elicio Therapeutics Competitors	-846.28%	-107.82%	-27.64%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elicio Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	1	4	0	2.50
Elicio Therapeutics Competitors	8816	13398	40769	1416	2.54

Elicio Therapeutics presently has a consensus target price of $19.75, suggesting a potential upside of 513.35%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 51.36%. Given Elicio Therapeutics’ higher possible upside, equities analysts plainly believe Elicio Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares Elicio Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elicio Therapeutics	N/A	-$39.57 million	-1.34
Elicio Therapeutics Competitors	$917.38 million	$68.12 million	-30.50

Elicio Therapeutics’ competitors have higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Elicio Therapeutics competitors beat Elicio Therapeutics on 7 of the 13 factors compared.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.